Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Peripheral blood progenitor cell transplantation: economic issues.

Yee GC.

Pharmacotherapy. 1998 Jan-Feb;18(1 Pt 2):9S-16S. Review.

PMID:
9473174
[PubMed - indexed for MEDLINE]
2.

Reduced charges and costs associated with outpatient autologous stem cell transplantation.

Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD.

Bone Marrow Transplant. 1998 May;21(9):927-32.

PMID:
9613786
[PubMed - indexed for MEDLINE]
Free Article
3.

Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.

Vicent MG, Madero L, Chamorro L, Madero R, Diaz MA.

Haematologica. 2001 Oct;86(10):1087-94.

PMID:
11602415
[PubMed - indexed for MEDLINE]
Free Article
4.

[Peripheral blood stem cell transplantation: current status and perspectives].

Colombat P.

Bull Cancer. 1995;82 Suppl 1:42s-48s. Review. French.

PMID:
7542943
[PubMed - indexed for MEDLINE]
5.

Peripheral blood progenitor cell transplantation for breast cancer: pharmacoeconomic considerations.

Gilbert CJ.

Pharmacotherapy. 1996 May-Jun;16(3 Pt 2):101S-108S.

PMID:
8726589
[PubMed - indexed for MEDLINE]
6.

The clinical effectiveness and financial impact of utilizing peripheral blood progenitor cells as rescue therapy following autologous bone marrow transplant.

Kucharski AJ, Ghalie R, Greenstein S, Matuszewski K.

Int J Technol Assess Health Care. 1996 Winter;12(1):172-9.

PMID:
8690558
[PubMed - indexed for MEDLINE]
7.

High-dose chemotherapy with autologous stem cell rescue in the outpatient setting.

Dix SP, Geller RB.

Oncology (Williston Park). 2000 Feb;14(2):171-85; discussion 185-6, 191-2. Review.

PMID:
10736807
[PubMed - indexed for MEDLINE]
8.

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.

McGuire WP.

Curr Probl Cancer. 1998 May-Jun;22(3):135-77. Review.

PMID:
9659570
[PubMed - indexed for MEDLINE]
9.

Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy.

Glaspy JA.

Bone Marrow Transplant. 1999 May;23 Suppl 2:S21-7. Review.

PMID:
10335873
[PubMed - indexed for MEDLINE]
Free Article
10.
11.

Economic aspects of high-dose chemotherapy: a clinician's perspective review.

Cetto GL, Molino A.

Crit Rev Oncol Hematol. 2002 Feb;41(2):251-67. Review.

PMID:
11856600
[PubMed - indexed for MEDLINE]
12.

Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with solid tumors.

Astier MP, Mayordomo JI, Abad JM, Gómez LI, Tres A.

Ann Oncol. 2000 May;11(5):603-6.

PMID:
10907956
[PubMed - indexed for MEDLINE]
Free Article
13.

[Economic evaluation of blood stem-cells autologous transplantation].

Corroller AG, Fortanier C, Faucher C, Blaise D, Moatti JP.

Bull Cancer. 2001 Sep;88(9):893-9. French.

PMID:
11604363
[PubMed - indexed for MEDLINE]
14.

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.

Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E.

Lancet. 1998 Aug 15;352(9127):515-21.

PMID:
9716055
[PubMed - indexed for MEDLINE]
15.

The economic evaluation of hematopoietic growth factors in high-dose chemotherapy.

Le Corroller AG, Moatti JP.

Anticancer Drugs. 1998 Nov;9(10):917-24. Review.

PMID:
9890703
[PubMed - indexed for MEDLINE]
16.

Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.

Vellenga E, van Agthoven M, Croockewit AJ, Verdonck LF, Wijermans PJ, van Oers MH, Volkers CP, van Imhoff GW, Kingma T, Uyl-de Groot CA, Fibbe WE.

Br J Haematol. 2001 Aug;114(2):319-26.

PMID:
11529850
[PubMed - indexed for MEDLINE]
17.

Optimization of peripheral blood stem cell collection by leukopheresis. Interaction between economic and clinical assessment of an innovation.

Le Corroller AG, Moatti JP, Chabannon C, Faucher C, Fortanier C, Ladaique P, Blache JL, Novakovitch G, Maraninchi D, Blaise D.

Int J Technol Assess Health Care. 1999 Winter;15(1):161-72.

PMID:
10407603
[PubMed - indexed for MEDLINE]
18.

Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.

Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, Jackman JA, Suzuki S, Styler MJ, Crilley PA, Klumpp TR, Mangan KF, Glick JH.

Bone Marrow Transplant. 2003 Feb;31(3):205-10.

PMID:
12621482
[PubMed - indexed for MEDLINE]
19.

Cytokines in haemopoietic progenitor mobilisation for peripheral blood stem cell transplantation.

Filshie RJ.

Curr Pharm Des. 2002;8(5):379-94. Review.

PMID:
12069376
[PubMed - indexed for MEDLINE]
20.

Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.

Filip S, Bláha M, Odrázka K, Mericka P, Vávrová J.

J Hematother Stem Cell Res. 2000 Feb;9(1):31-8.

PMID:
10738969
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk